Trim 25-30% LRCX exposure into $315-320 zone; tighten stop to $270-275; retain 70-75% core through Q3 FY26 earnings catalyst
Underweight rating reflects a decisive trim of 25-30% into the $315-320 zone while preserving 70-75% core exposure, justified by broken technicals (price $301.90 below 10 EMA, 50 SMA at $331, VWMA; lower Bollinger Band at $291), elevated cyclical risk (receivables surge to $5.34B, OCF/NI at 81%, WFE peak signature matching 2000/2007/2010/2021-22 patterns), and macro headwinds (Polymarket ~1% September cut probability, ~10% December, 1.87x beta amplifying market drawdowns). The structural thesis remains intact (200 SMA at $257 intact at 17% above, 65% ROE, 30% revenue growth, $2.28B deferred revenue, $1.85B net cash, 51.7% gross margins, AI/HBM capex visibility into 2027) supporting retention. Stop tightened to $270-275 (above 200 SMA, just over 1x ATR) with Q3 FY26 earnings as the binary catalyst; guidance commentary on order book and China exposure matters more than headline ~$2.85 EPS consensus.
| Position | Action |
|---|---|
| Current position | Trim 25-30% of LRCX exposure via staged sales into $315-320 zone over 1-2 weeks |
| Retained position | Retain 70-75% core for structural thesis |
| Remaining position hedge | Consider 10-15% short-dated put hedge through Q3 FY26 earnings |
| Fresh capital | Avoid fresh capital deployment at current levels |
The bear is confusing a healthy mid-cycle consolidation with a structural breakdown—the underlying business is hitting on all cylinders with record earnings, expanding margins, and a multi-year AI capex tailwind that makes this pullback a gift, not a warning.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 313.51 | bearish |
| 50 SMA | 331.21 | bearish |
| 200 SMA | 257.11 | bullish |
| RSI (14) | 44.42 | neutral |
| MACD | -2.35 | bearish |
| MACD Signal | -2.01 | bearish |
| MACD Histogram | -0.34 | neutral |
| ATR (14) | 18.19 | neutral |
| Bollinger Upper Band | 340.14 | neutral |
| Bollinger Mid Band | 315.59 | neutral |
| Bollinger Lower Band | 291.05 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Constructive retest of $252-257 with stabilizing AR/DSO and bullish price action
Then: Re-engage/add to long position
The AI capex super-cycle is a multi-year structural commitment, not a near-term trade
↩ rebuts: “The bear's 'good news, weak price' framing misses the first innings of an AI-driven WFE super-cycle”
EV: $400+ (test of prior highs) · concedes: Near-term technical setup is challenging: price below 10 EMA and 50 SMA, MACD has rolled over, RSI is sub-50; A sustained close below $270 combined with Fed-driven liquidity drain that genuinely threatens hyperscaler capex budgets would be a valid reconsider signal
Peak-cycle fundamentals, rich valuations (30.3x P/B, 52.3x TTM P/E), and restrictive macro create asymmetric downside risk — an excellent company can still be a bad stock at the wrong price, in the wrong cycle, with the wrong macro backdrop.
EV: -$70 to -$100 (30%+ further downside from ~$301 to $200-220 in bear scenario) · concedes: Fundamentals cited by bull are real — Q4 FY26 net income $2.28B, gross margin 51.8%, operating margin 37.4%; LRCX is an excellent company, not a bad business; AI structural demand thesis has merit; Forward EPS estimate could prove accurate if all conditions align (20% bull probability)
→ vs neutral: Waiting for stabilization or modest trim is the wrong optimization — by the time the 50 SMA at $331 is reclaimed, you'll be selling 10% lower; decisive action captures the bulk of the move
→ vs conservative: The 27% dividend hike and 26% revenue growth are not reasons to hold — at 52x earnings, you're not being paid to wait; 0.33% yield doesn't compensate for the risk
→ vs conservative: Buybacks shrinking share count in a ~$400B company is not price appreciation; R&D lab groundbreaking is a 5-year capex commitment that doesn't generate near-term revenue
→ vs neutral: Anchoring on fundamentals (ROE 65%, 51.8% margins) while ignoring the 52x trailing earnings multiple for a cyclical is intellectual dishonesty — the multiple assumes perfection never delivered by a cyclica
| bearish |
| VWMA | 319.64 | bearish |
| Latest Close | 301.90 | bearish |
Support: 291.05 · 269.61 · 252.35 | Resistance: 313.51 · 315.59 · 331.21 · 340.14
LRCX has transitioned from a strong uptrend (peaking at $438.50 on June 30) into a sharp, high-volatility correction. Price is below short-term momentum indicators but well above the 200 SMA — a "trend under pressure" rather than a full structural breakdown. The long-term uptrend is technically intact, but the near-term picture is decisively bearish. A defensive posture (trim, hedge, or wait for stabilization) is warranted. A close back above the 10 EMA ($313.51) would be the first sign of stabilization, while a daily close below $291.05 would open the door to the $252-270 zone — approximately 15-20% further downside.
Market Cap
$377.8B
P/E (TTM)
52.3x
Forward P/E
26.1x
PEG Ratio
1.46
Price/Book
30.3x
Beta
1.87
Dividend Yield
0.33%
52-Week High
$438.50
52-Week Low
$94.11
Revenue (TTM)
$23.23B
Revenue YoY (FY26)
+26.0%
Gross Margin (TTM)
50.5%
Operating Margin (TTM)
37.4%
Net Margin (TTM)
31.3%
ROE
65.1%
ROA
22.8%
Debt/Equity
33.0%
Current Ratio
2.63x
Cash & Equivalents
$5.58B
Long-Term Debt
$3.72B
Net Cash
~$1.86B
Stockholders' Equity
$12.47B
Operating Cash Flow (FY26)
$5.86B
Free Cash Flow (FY26)
$4.89B
FCF Margin
21.1%
Dividends Paid (FY26)
$1.27B
Buybacks (FY26)
$3.85B
Diluted Shares (Jun-26)
1,256M
Diluted EPS (TTM)
$5.77
Diluted EPS (FY26)
$5.76
Forward EPS
$11.56
Q4 FY26 Revenue
$6,722M
Q4 FY26 Net Income
$2,277M
Q4 FY26 Gross Margin
51.8%
Q4 FY26 Operating Margin
37.4%
Q4 FY26 Diluted EPS
$1.81
Receivables (Jun-26)
$5,340M
Inventory (Jun-26)
$4,276M
R&D Expense (FY26)
$2,376M
FY2025 Revenue
$18,436M
FY2024 Revenue
$14,905M
FY2023 Revenue
$17,429M
Strengths
Concerns
Lam Research is a leading wafer fabrication equipment supplier ("Big 3" in WFE) benefiting from AI, HBM, and advanced packaging secular tailwinds. The company is in a strong cyclical upturn with accelerating revenue growth (+26% YoY to $23.2B in FY26), record quarterly earnings ($2.28B net income in Q4 FY26), and expanding margins (gross 50.5%, operating 37.4%) driven by operating leverage on its high-fixed-cost installed base. Exceptional capital returns (~$5.1B to shareholders in FY26) and a net cash balance sheet support EPS growth, but the stock trades at a stretched 52x TTM P/E with high beta of 1.87 and rising receivables warrant careful monitoring for entry timing and position sizing.
Macro: The macro backdrop is characterized by a rapid repricing away from Fed easing toward potential rate hikes, driven by hawkish expectations around Kevin Warsh's potential Fed role. Inflation concerns are dominating market narrative over growth concerns, with recession odds remaining very low at 8%. Gold prices have fallen on Warsh-related inflation concerns, serving as a rate-sensitivity tell for broader risk assets. The shift toward higher-for-longer rates creates a challenging environment for high-multiple growth equities like LRCX.